HUTCHMED (NASDAQ:HCM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

HCM has been the topic of a number of other research reports. Zacks Research lowered shares of HUTCHMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 9th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th. Morgan Stanley lowered HUTCHMED from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $18.00 to $13.75 in a research note on Monday, September 22nd. Finally, Bank of America lifted their price target on HUTCHMED from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, July 22nd. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Trading Up 2.1%

Shares of HUTCHMED stock opened at $15.39 on Friday. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $21.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. The company’s 50 day moving average price is $16.07 and its two-hundred day moving average price is $15.49.

Hedge Funds Weigh In On HUTCHMED

Institutional investors have recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. lifted its stake in HUTCHMED by 31.4% in the first quarter. Crossmark Global Holdings Inc. now owns 24,420 shares of the company’s stock valued at $367,000 after buying an additional 5,829 shares during the period. Bank of America Corp DE lifted its stake in HUTCHMED by 40.4% in the fourth quarter. Bank of America Corp DE now owns 22,723 shares of the company’s stock valued at $327,000 after buying an additional 6,540 shares during the period. Goldman Sachs Group Inc. lifted its stake in HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after buying an additional 7,342 shares during the period. Vident Advisory LLC lifted its stake in HUTCHMED by 78.3% in the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock valued at $297,000 after buying an additional 8,664 shares during the period. Finally, XY Capital Ltd lifted its stake in HUTCHMED by 142.4% in the first quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock valued at $1,702,000 after buying an additional 66,460 shares during the period. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.